Xeltis Hemodialysis Access Graft (aXess) US Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 140 participants.

Also called NCT06494631

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 140 participants (planned count) (from the registry)
Sponsor
  • Xeltis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06494631
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT06494631. Allocation not applicable; no masking; primary purpose treatment. Start 2024-11-11 (actual); primary completion 2028-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Xeltis Hemodialysis Access Graft (aXess) US Study
Condition
End Stage Renal Disease
Intervention (Device)
Xeltis Hemodialysis Access (aXess) graft
Lead sponsor
Xeltis (class: industry)

Record details

Record id
cardio:ct-nct06494631
Content hash
f9da6d92b1566727135c001a04c5e930526a3c852f7ce9283b5364d448f37ecc